Copyright
©The Author(s) 2023.
World J Hepatol. Jan 27, 2023; 15(1): 68-78
Published online Jan 27, 2023. doi: 10.4254/wjh.v15.i1.68
Published online Jan 27, 2023. doi: 10.4254/wjh.v15.i1.68
Variables | Before propensity score matching | After propensity score matching | ||||
AIH (n = 375) | Non-CLD (n = 1647915) | P value | AIH (n = 375) | Non-CLD (n = 375) | P value | |
Age, yr, mean ± SD | 53.1 ± 18.4 | 46.4 ± 18.8 | < 0.01 | 53.1 ± 8.4 | 53.2 ± 8.2 | 0.97 |
Sex, n (%) | ||||||
Female | 271 (72.2) | 893768 (54.2) | < 0.01 | 271 (72.2) | 256 (68.2) | 0.23 |
Ethnicity, n (%) | ||||||
Hispanic or Latino | 37 (9.8) | 144535 (8.7) | 0.45 | 37 (9.8) | 36 (9.6) | 0.90 |
Race, n (%) | ||||||
White | 238 (63.4) | 1028824 (62.4) | 0.68 | 238 (63.4) | 228 (60.8) | 0.45 |
Black or African American | 64 (17.1) | 245820 (14.9) | 0.24 | 64 (17.1) | 69 (18.4) | 0.63 |
Other | 65 (17.3) | 325638 (19.7) | 0.24 | 65 (17.3) | 69 (18.4) | 0.70 |
Nicotine dependence, n (%) | 76 (20.2) | 181270 (10.9) | < 0.01 | 72 (19.2) | 74 (19.7) | 0.67 |
BMI (kg/m2), mean ± SD | 28.9 ± 7.05 | 29.9 ± 7.45 | 0.07 | 28.9 ± 7.05 | 30.8 ± 7.65 | 0.01 |
Comorbidities, n (%) | ||||||
Hypertension | 163 (43.4) | 384968 (23.3) | < 0.01 | 163 (43.4) | 159 (42.4) | 0.77 |
Ischemic heart diseases | 59 (15.7) | 119162 (7.2) | < 0.01 | 59 (15.7) | 57 (15.2) | 0.84 |
Heart failure | 38 (10.1) | 65245 (3.9) | < 0.01 | 38 (10.1) | 37 (9.8) | 0.90 |
Diabetes | 74 (19.7) | 171727 (10.4) | < 0.01 | 74 (19.7) | 68 (18.1) | 0.58 |
Chronic lower respiratory diseases | 82 (21.8) | 235406 (14.2) | < 0.01 | 82 (21.8) | 81 (21.6) | 0.93 |
Cerebrovascular diseases | 37 (9.8) | 73209 (4.4) | < 0.01 | 37 (9.8) | 39 (10.4) | 0.81 |
CKD of any stage | 46 (12.2) | 78265 (4.7) | < 0.01 | 46 (12.2) | 37 (9.8) | 0.29 |
Neoplasms | 125 (33.3) | 293362 (17.8) | < 0.01 | 125 (33.3) | 132 (35.2) | 0.59 |
Variables | Before propensity score matching | After propensity score matching | ||||
AIH (n = 375) | Non-AIH CLD (n = 15790) | P value | AIH (n = 363) | Non-AIH CLD (n = 363) | P value | |
Age, yr, mean ± SD | 53.1 ± 18.5 | 60.3 ± 12.1 | < 0.01 | 53.9 ± 18.1 | 54.3 ± 15.5 | 0.76 |
Sex, n (%) | ||||||
Female | 267 (71.2) | 6517 (41.2) | < 0.01 | 262 (72.1) | 266 (73.2) | 0.74 |
Ethnicity, n (%) | ||||||
Hispanic or Latino | 82 (21.8) | 1579 (10) | < 0.01 | 82 (22.5) | 67 (18.4) | 0.19 |
Race, n (%) | ||||||
White | 236 (62.9) | 11132 (70.5) | 0.02 | 235 (64.7) | 218 (60.1) | 0.19 |
Black or African American | 65 (17.3) | 2462 (15.5) | 0.41 | 58 (15.9) | 72 (19.8) | 0.17 |
Other | 66 (17.6) | 1824 (11.5) | 0.04 | 62 (17.1) | 61 (16.8) | 0.92 |
Nicotine dependence, n (%) | 87 (23.2) | 1831 (11.5) | < 0.01 | 89 (24.5) | 87 (23.9) | 0.94 |
BMI (kg/m2), mean ± SD | 28.9 ± 7.1 | 30.4 ± 7.48 | 0.09 | 29 ± 7.11 | 28.7 ± 7.79 | 0.72 |
Comorbidities, n (%) | ||||||
Hypertension | 165 (44) | 11469 (72.6) | < 0.01 | 161 (44.3) | 200 (55.1) | 0.03 |
Ischemic heart diseases | 62 (16.5) | 5472 (34.6) | < 0.01 | 59 (16.2) | 56 (15.4) | 0.76 |
Heart failure | 39 (10.4) | 4196 (26.5) | < 0.01 | 38 (10.4) | 48 (13.2) | 0.25 |
Diabetes | 74 (19.7) | 7882 (49.9) | 0.01 | 74 (20.4) | 66 (18.1) | 0.45 |
Chronic lower respiratory diseases | 84 (22.4) | 5843 (37.0) | < 0.01 | 82 (22.5) | 79 (21.7) | 0.79 |
Cerebrovascular diseases | 37 (9.8) | 3079 (19.4) | < 0.01 | 37 (10.1) | 39 (10.7) | 0.81 |
CKD of any stage | 49 (13.1) | 5102 (32.3) | < 0.01 | 46 (12.6) | 55 (15.1) | 0.33 |
Neoplasms | 131 (34.9) | 8400 (53.1) | < 0.01 | 124 (34.1) | 131 (36.1) | 0.59 |
- Citation: Krishnan A, Patel RA, Hadi YB, Mukherjee D, Shabih S, Thakkar S, Singh S, Woreta TA, Alqahtani SA. Clinical characteristics and outcomes of COVID-19 in patients with autoimmune hepatitis: A population-based matched cohort study. World J Hepatol 2023; 15(1): 68-78
- URL: https://www.wjgnet.com/1948-5182/full/v15/i1/68.htm
- DOI: https://dx.doi.org/10.4254/wjh.v15.i1.68